RxDoctor Payments Data

Lawrence Cooper, MD

Internal Medicine · Santa Rosa, CANPI 1801895602

Payments from drug & device makers

$2,847in general payments, 2019–2025

Across 139 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$931
  • AbbVie$556
  • Amgen$398
  • E.r. Squibb & Sons, L.L.C.$116
  • Johnson & Johnson$107
  • Novo Nordisk$100
  • plus $640 from 20 others

What the payments were for

  • Food & beverage$2,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,847 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$250,201
Medicare patients
638
Services billed
6,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$131,772
OzempicSemaglutide42$51,307
JanuviaSitagliptin Phosphate26$40,186
JardianceEmpagliflozin29$38,970
Nurtec OdtRimegepant Sulfate12$26,508
XareltoRivaroxaban16$21,257
Spiriva HandihalerTiotropium Bromide24$16,934
MyrbetriqMirabegron17$15,715
Spiriva RespimatTiotropium Bromide15$14,719
PremarinEstrogens, Conjugated25$12,384
Breo ElliptaFluticasone/Vilanterol15$11,824
Levothyroxine Sodium652$10,094
Atorvastatin Calcium696$7,884
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$7,624
TrintellixVortioxetine Hydrobromide19$7,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Premarin$931$170,664152 claims
Boehringer IngelheimJardiance, Spiriva Respimat$16$53,68944 claims
Novo NordiskOzempic$100$51,30742 claims
Johnson & JohnsonXarelto$107$21,25716 claims
Astellas Pharma US IncMyrbetriq$12$15,71517 claims
GSKBreo Ellipta$51$11,82415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →